Gilead Maintains Optimistic Outlook For Yescarta Despite Slow Growth
Executive Summary
Gilead projects roughly $200m in sales growth for its CAR-T product Yescarta, despite the drug’s modest $6m sequential growth during the fourth quarter. For 2019 overall sales, the company projects slight growth, if any.
You may also be interested in...
Gilead Writes Down Kite Buy As Yescarta Sales Flatten Out
Gilead takes $800m impairment charge against Kite acquisition a year after an $820m write-down. Kite and Yescarta are appear to be afterthoughts in discussions of Gilead’s portfolio and pipeline.
Gilead Says Sluggish Yescarta Business Will Continue To Fluctuate
The CAR-T therapy’s sales declined 2% from the previous quarter, although EU sales are growing briskly. The HIV franchise posted its best quarter ever, but the company’s overall financial performance was flat.
Biktarvy, PrEP Continue Driving Gilead’s HIV Dominance
HIV remains the main growth franchise for Gilead, despite an anticipated first quarter revenue downturn due to inventory and payer mix. Biktarvy’s launch and growth in PrEP business provide multiple drivers for the franchise.